Cutting edge: engagement of CD160 by its HLA-C physiological ligand triggers a unique cytokine profile secretion in the cytotoxic peripheral blood NK cell subset.
CD160 is an Ig-like activating NK cell receptor expressed on the majority of circulating NK cells. This population corresponds to the nonproliferating, highly cytolytic, CD56dimCD16+ subset. CD160 engagement by HLA-C molecules mediates cytotoxic function. In this study, we report that upon specific activation by the physiological ligand HLA-C, or Ab cross-linking, CD160+ peripheral blood NK cells produce IFN-gamma, TNF-alpha, and IL-6. This unique CD160-mediated cytokine production differs from the one observed after CD16 engagement whose expression is also restricted to the CD56dim cytotoxic NK cell subset. As already reported for the CD160-mediated cytotoxic effector function, CD160-mediated cytokine production by peripheral blood-NK cells is negatively controlled by the killer Ig-like receptor CD158b. Thus, the CD160 receptor represents a unique triggering surface molecule expressed by cytotoxic NK cells that participates in the inflammatory response and determines the type of subsequent specific immunity.
Barakonyi
Aliz
A
Institut National de la Santé et de la Recherche Médicale (INSERM) Unité 563, Centre de Physiopathologie Toulouse-Purpan, Toulouse, France.
Rabot
Magali
M
Marie-Cardine
Anne
A
Aguerre-Girr
Maryse
M
Polgar
Beata
B
Schiavon
Valérie
V
Bensussan
Armand
A
Le Bouteiller
Philippe
P
D000911:Antibodies, Monoclonal / Q000378:metabolism; D015703:Antigens, CD / Q000096:biosynthesis / Q000097:blood / Q000276:immunology / Q000502:physiology*; D002478:Cells, Cultured; D003432:Cross-Linking Reagents / Q000378:metabolism; D016207:Cytokines / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000097:blood / Q000378:metabolism*; D003601:Cytotoxicity Tests, Immunologic; D003602:Cytotoxicity, Immunologic; D058851:GPI-Linked Proteins; D015236:HLA-C Antigens / Q000096:biosynthesis / Q000097:blood / Q000502:physiology*; D006801:Humans; D007371:Interferon-gamma / Q000096:biosynthesis; D015850:Interleukin-6 / Q000096:biosynthesis; D020014:K562 Cells; D007694:Killer Cells, Natural / Q000276:immunology* / Q000378:metabolism*; D008024:Ligands; D016131:Lymphocyte Subsets / Q000276:immunology* / Q000378:metabolism*; D008565:Membrane Proteins / Q000096:biosynthesis / Q000097:blood / Q000276:immunology / Q000502:physiology*; D017452:Receptors, IgG / Q000097:blood / Q000276:immunology; D011971:Receptors, Immunologic / Q000096:biosynthesis / Q000097:blood / Q000276:immunology / Q000502:physiology*; D054340:Receptors, KIR; D054344:Receptors, KIR2DL3; D055607:Receptors, Natural Killer Cell; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis
D000911:Antibodies, Monoclonal; D015703:Antigens, CD; C114505:CD160 protein, human; D003432:Cross-Linking Reagents; D016207:Cytokines; D058851:GPI-Linked Proteins; D015236:HLA-C Antigens; D015850:Interleukin-6; D008024:Ligands; D008565:Membrane Proteins; D017452:Receptors, IgG; D011971:Receptors, Immunologic; D054340:Receptors, KIR; D054344:Receptors, KIR2DL3; D055607:Receptors, Natural Killer Cell; D014409:Tumor Necrosis Factor-alpha; D007371:Interferon-gamma